MedTrace Logo

An Open-Label Safety Study of A-101 Solution

NCT02667288 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 147

Last updated 2018-02-07

Study results available
· View outcomes & findings →

Summary

This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.

Conditions

  • Seborrheic Keratosis

Interventions

DRUG

A-101 Solution

Sponsors & Collaborators

  • Aclaris Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Stuart D Shanler, MD · Aclaris Therapeutics, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02667288 on ClinicalTrials.gov